Kindred Biosciences Named Best Company in North America by Leading Industry Publication

San Francisco, CA. (January 22, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio’s transition to a […]

Kindred Biosciences Announces Pricing of Public Offering

SAN FRANCISCO, California. (January 18, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount […]

Kindred Biosciences Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, California. (January 17, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a […]

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

SAN FRANCISCO, CA (January 14, 2019) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In […]

Kindred Biosciences Announces Third Quarter 2018 Financial Results

San Francisco, CA (November 7, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided updates on its programs. For the third quarter 2018, KindredBio reported net product revenues of $0.6 million and […]